Investors looking to find high-potential stocks frequently use systematic methods that mix strict technical study with basic growth measures. One well-known method is the Mark Minervini strategy, which uses a defined Trend Template to find stocks in clear, strong uptrends. This technical list confirms a stock is showing leading traits, trading above important moving averages, and displaying good relative strength. To add to this, the strategy focuses on the need for basic business speed, looking for firms with quickening earnings and sales growth—a sign of real market leaders. This joined filter of technical health and basic speed creates the foundation for a "High Growth Momentum + Trend Template" screen, made to find stocks that are both trending positively and supported by solid business results.
Tarsus Pharmaceuticals Inc (NASDAQ:TARS), a clinical-stage biopharmaceutical company, recently appeared from this kind of screening process. We will look at how it fits the two requirements of the Minervini Trend Template and high-growth basic standards.
Fit with the Minervini Trend Template
The Minervini Trend Template is a strict group of technical rules made to sort for stocks in a Stage 2 advance, the period where the largest gains usually happen. It concentrates on the order of moving averages, nearness to highs, and better relative strength. A check of TARS shows it passes these important technical marks:
- Moving Average Order: The stock price is now trading above its rising 50-day, 150-day, and 200-day simple moving averages (SMAs). Importantly, the 50-day SMA ($72.34) is above the 150-day SMA ($66.38), which is above the rising 200-day SMA ($60.25). This ordered, upward-sloping arrangement is a standard sign of a firm, set uptrend and a central part of the Trend Template.
- Nearness to Highs: A main Minervini rule is to concentrate on strength, not weakness. TARS's present price is about 96% above its 52-week low of $38.51, showing major recovery and speed. Also, it is trading within 12% of its 52-week high of $85.25, showing it is acting like a market leader set for possible breakout moves, not a laggard.
- Better Relative Strength: The stock has a ChartMill Relative Strength (CRS) score of 85.87, meaning it has done better than almost 86% of the market over the last year. Minervini states that the top performers are usually those already showing leadership, and a high RS score is a direct measure of that leadership.
This technical view confirms TARS is in a positive trend. The recent price movement, marked by a firm move off support and higher volume, fits the strategy's aim of entering stocks as they continue their uptrend after a time of holding.
Basics Backing High Growth Momentum
While the Trend Template deals with the "when" to buy, the "why" is based in the company's basic path. The High Growth Momentum (HGM) score judges the quickening and quality of a company's financial results. TARS shows several strong growth measures that support its screening outcome:
- Very High Revenue Growth: The company is in a high-growth stage. Year-over-year revenue growth is at a notable 146.7%. More notable is the steadiness of this increase, with recent quarterly sales growth numbers from 128% to 183%. This shows not just growth, but firm and continued speed in its business activities, a main filter for growth investors.
- Earnings Path and Analyst View: Although the company is not yet making money—usual for clinical-stage biopharms—the trend in its bottom line is getting much better. The EPS loss has become much smaller, with year-over-year growth of 47.7%. Analyst opinion is clearly positive, with agreement estimates for next year's earnings moved up by over 37% in the last three months. Such upward changes are often a sign of positive price speed, as they show growing belief in the company's future profits.
- Business Catalysts: TARS's basic story is pushed by the sale of its lead product, XDEMVY, for Demodex blepharitis, and its work on other conditions. The very high revenue growth is a direct result of early business success, giving the clear catalyst that Minervini's strategy looks for—a basic reason for the improving technical view.
Technical Condition and Present Position
According to ChartMill's own study, TARS gets a firm Technical Rating of 8 out of 10, confirming its strong uptrend and market-leading results. The report states the short-term trend is positive and the stock has been a top performer over the past year. However, the study also gives important setting for entry timing. The Setup Quality rating is now a 3, showing that while the stock is technically sound, it has become stretched after its recent rise and is in a changeable trading range. The summary notes that this may not offer a perfect, low-risk entry point now and proposes waiting for a possible holding period to form a clearer pattern.
For a full look at the support and resistance levels, volume study, and moving average arrangements, you can see the complete Technical Analysis Report for TARS.
Locating Like Chances
Tarsus Pharmaceuticals shows the kind of chance that systematic screening can reveal: a company with a strong basic catalyst appearing in a technically sound chart formation. For investors wanting to use this joined "High Growth Momentum + Trend Template" method to locate other possible choices, the set screen is ready for use. You can view the present screening results and change settings to match your own standards through this link: High Growth Momentum + Trend Template Screen.
Disclaimer: This article is for information and learning only. It is not advice to buy or sell any security. The study is based on given data and described screening methods. All investing has risk, including the chance of losing the original amount. You should do your own study and talk with a qualified financial advisor before making any investment choices.
